Psoriatic Arthritis Trial, Recruiting NCT06382051 Sponsor: Novartis Pharmaceuticals Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Psoriatic Arthritis Trial, Recruiting

NCT06382051
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have moderate-to-severe plaque psoriasis (a skin condition causing thick, scaly patches) and your doctor believes you are a good candidate for a type of advanced medication called a biologic
  • You are an adult at the time you sign the consent form to join the study
  • You are willing and able to follow the study's instructions and requirements
  • You currently live in Canada

Who may not be able to join:

  • You have previously tested positive for psoriatic arthritis (a type of joint inflammation linked to psoriasis) through a screening questionnaire called PEST
  • You have already been diagnosed with psoriatic arthritis
  • You have been diagnosed with another type of inflammatory joint condition not related to psoriasis, such as rheumatoid arthritis, reactive arthritis, enteropathic arthritis, or axial spondyloarthritis (confirm with trial site if unsure about your diagnosis)
  • You have been treated with a biologic medication (an advanced, targeted drug) for psoriasis or any other condition in the 6 months before joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 January 2025
Est. completion
28 August 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov